Beijing Sun Novo Pharmaceutical Research Co Ltd (SHG:688621) — Market Cap & Net Worth
Market Cap & Net Worth: Beijing Sun Novo Pharmaceutical Research Co Ltd (688621)
Beijing Sun Novo Pharmaceutical Research Co Ltd (SHG:688621) has a market capitalization of $1.22 Billion (CN¥8.35 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #8117 globally and #1885 in its home market, demonstrating a 5.56% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing Sun Novo Pharmaceutical Research Co Ltd's stock price CN¥74.55 by its total outstanding shares 112000000 (112.00 Million). Also see how large is Beijing Sun Novo Pharmaceutical Research's balance sheet for a full breakdown of the balance sheet.
Beijing Sun Novo Pharmaceutical Research Co Ltd Market Cap History: 2021 to 2026
Beijing Sun Novo Pharmaceutical Research Co Ltd's market capitalization history from 2021 to 2026. Data shows change from $1.40 Billion to $1.22 Billion (-2.32% CAGR). Also see how efficiently does Beijing Sun Novo Pharmaceutical Research generate cash for how efficiently the company converts equity into cash flow.
Beijing Sun Novo Pharmaceutical Research Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing Sun Novo Pharmaceutical Research Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Beijing Sun Novo Pharmaceutical Research for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.84x
Beijing Sun Novo Pharmaceutical Research Co Ltd's market cap is 0.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.19x
Beijing Sun Novo Pharmaceutical Research Co Ltd's market cap is 5.19 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.40 Billion | $493.65 Million | $105.66 Million | 2.84x | 13.25x |
| 2022 | $1.18 Billion | $676.61 Million | $156.47 Million | 1.75x | 7.56x |
| 2023 | $1.14 Billion | $932.12 Million | $184.76 Million | 1.22x | 6.16x |
| 2024 | $617.87 Million | $1.08 Billion | $177.41 Million | 0.57x | 3.48x |
| 2025 | $1.02 Billion | $1.22 Billion | $196.08 Million | 0.84x | 5.19x |
Competitor Companies of 688621 by Market Capitalization
Companies near Beijing Sun Novo Pharmaceutical Research Co Ltd in the global market cap rankings as of September 24, 2026. Review Beijing Sun Novo Pharmaceutical Research tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Beijing Sun Novo Pharmaceutical Research Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #586 globally with a market cap of $46.44 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #651 globally with a market cap of $42.68 Billion USD ( CN¥291.65 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #586 | GALDERMA GROUP AG | NYSE:GALDY | $46.44 Billion | $39.83 |
| #638 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #651 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.68 Billion | CN¥45.72 |
Beijing Sun Novo Pharmaceutical Research Co Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Beijing Sun Novo Pharmaceutical Research Co Ltd's market cap moved from $1.40 Billion to $ 1.22 Billion, with a yearly change of -2.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.22 Billion | +19.95% |
| 2025 | CN¥1.02 Billion | +64.85% |
| 2024 | CN¥617.87 Million | -45.73% |
| 2023 | CN¥1.14 Billion | -3.70% |
| 2022 | CN¥1.18 Billion | -15.54% |
| 2021 | CN¥1.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Beijing Sun Novo Pharmaceutical Research Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.22 Billion USD |
| MoneyControl | $1.22 Billion USD |
| MarketWatch | $1.22 Billion USD |
| marketcap.company | $1.22 Billion USD |
| Reuters | $1.22 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platfo… Read more